Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab maintenance in advanced NSCLC
NCT00312975Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2006
- Primary completion
- Apr 2008
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Tremelimumab with Best Supportive Care (2 arms). Primary endpoint: Progression-Free Survival at 2 years. Started May 2006; status: completed.
02
Drugs
tremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00312975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00312975.